# Charles River Laboratories International Moat

Status: published. Policy: company-analysis-1.

Charles River demonstrates scientific differentiation, selective realized price increases and microbial-testing share gains. Its infrastructure and client engagement support a possible intangible-asset advantage, but the passages do not establish durable company-wide barriers or switching costs. Customer losses, persistent restructuring and declining underlying margins show vulnerabilities. Improving bookings and digital adoption provide offsets, while alternative testing methods threaten future demand. The evidence establishes neither a durable moat nor uniformly interchangeable offerings.

## intangible_assets

Scientific capabilities, specialized research-model production and microbial-testing platforms provide current differentiation. Reported endotoxin-testing share gains support competitive success in a specific business; durable protection across the portfolio remains unestablished.

Durability: A three-continent production infrastructure and established scientific portfolio could support persistence, but operating history and infrastructure alone do not demonstrate durable competitive exclusion.

Risks: Alternative testing methods could reduce animal-model demand. Specialized entrants face lower barriers in some activities. Actual CDMO customer losses demonstrate that scientific offerings do not ensure customer dependency; those businesses were subsequently divested.

Invalidation: The candidate advantage would weaken if microbial-testing share gains reverse, research-model price increases repeatedly coincide with customer migration, or alternative methods displace animal-based demand without replacement revenue from Charles River's newer capabilities.

Competitors: Not established
- [https://www.sec.gov/Archives/edgar/data/1100682/000110068226000022/crl-20251227.htm](https://www.sec.gov/Archives/edgar/data/1100682/000110068226000022/crl-20251227.htm) · 2026-02-18
- [https://www.sec.gov/Archives/edgar/data/1100682/000110068226000118/crl-20260627.htm](https://www.sec.gov/Archives/edgar/data/1100682/000110068226000118/crl-20260627.htm) · 2026-08-05
- [https://www.sec.gov/Archives/edgar/data/1100682/000110465926037367/tm261421-1_def14a.htm](https://www.sec.gov/Archives/edgar/data/1100682/000110465926037367/tm261421-1_def14a.htm) · 2026-03-31
- [https://www.sec.gov/Archives/edgar/data/1100682/000110068225000011/crl-20241228.htm](https://www.sec.gov/Archives/edgar/data/1100682/000110068225000011/crl-20241228.htm) · 2025-02-19
- [https://www.sec.gov/Archives/edgar/data/1100682/000110068224000007/crl-20231230.htm](https://www.sec.gov/Archives/edgar/data/1100682/000110068224000007/crl-20231230.htm) · 2024-02-14
- [https://www.sec.gov/Archives/edgar/data/1100682/000110068226000038/crl-20260328.htm](https://www.sec.gov/Archives/edgar/data/1100682/000110068226000038/crl-20260328.htm) · 2026-05-07
- [https://www.sec.gov/Archives/edgar/data/1100682/000110068226000142/crlinvestorday2026pressr.htm](https://www.sec.gov/Archives/edgar/data/1100682/000110068226000142/crlinvestorday2026pressr.htm) · 2026-09-24
- [https://www.sec.gov/Archives/edgar/data/1100682/000110068226000115/crl2q26earningsrelease.htm](https://www.sec.gov/Archives/edgar/data/1100682/000110068226000115/crl2q26earningsrelease.htm) · 2026-08-05
- [https://www.sec.gov/Archives/edgar/data/1100682/000110068226000036/crl1q26earningsrelease.htm](https://www.sec.gov/Archives/edgar/data/1100682/000110068226000036/crl1q26earningsrelease.htm) · 2026-05-07

[JSON](https://beanvest.com/stock/crl/moat.json)